Melanoma Targeted Therapies beyond <i>BRAF</i>-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches.

Cancers (Basel) · 2021 · PMC8616477 · PMID 34831002

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

in a smaller study ( n = 101) evaluating anti- CTLA-4 in NRAS and BRAF mutant melanomas, however, results did not reach statistical significance [ 90 ]. 4.1.4.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.